User: Guest  Login
Document type:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Article 
Author(s):
Hale, G; Rebello, P; Al Bakir, I; Bolam, E; Wiczling, P; Jusko, WJ; Vandemeulebroucke, E; Keymeulen, B; Mathieu, C; Ziegler, AG; Chatenoud, L; Waldmann, H 
Title:
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. 
Abstract:
Otelixizumab is a chimeric CD3 antibody that has been genetically engineered to remove the glycosylation site in the Fc domain. This limits its ability to bind to complement or Fc receptors and reduces the risk of adverse clinical reactions due to cytokine release. In a trial for treatment of type 1 diabetes, a short treatment with otelixizumab resulted in a reduced requirement for insulin lasting at least 18 months. In the course of this trial, the blood concentrations of the antibody were meas...    »
 
Journal title abbreviation:
J Clin Pharmacol 
Year:
2010 
Journal volume:
50 
Journal issue:
11 
Pages contribution:
1238-48 
Language:
eng 
Fulltext / DOI:
Print-ISSN:
0091-2700 
TUM Institution:
Klinik und Poliklinik für Kinderheilkunde und Jugendmedizin